Welcome to our dedicated page for Tango Therapeutics news (Ticker: TNGX), a resource for investors and traders seeking the latest updates and insights on Tango Therapeutics stock.
Tango Therapeutics, Inc. (TNGX) is a clinical-stage biotechnology company pioneering precision oncology solutions through innovative target discovery and therapeutic development. This page provides authorized updates on their research programs, clinical trials, and strategic initiatives in cancer treatment innovation.
Investors and researchers will find verified information about TNGX's pipeline progress, including PRMT5 inhibitor developments for CNS/non-CNS cancers and discontinued programs like TNG348. All content undergoes strict verification to ensure accuracy in reporting scientific milestones and regulatory updates.
Key coverage areas include clinical trial phases, research collaborations, peer-reviewed study publications, and corporate developments. The resource is particularly valuable for tracking therapies addressing tumor suppressor gene restoration and immune evasion mechanisms.
Bookmark this page for real-time updates on Tango Therapeutics' work in CRISPR-enabled drug discovery and their mission to transform cancer treatment paradigms through precision medicine approaches.
Tango Therapeutics (NASDAQ: TNGX) reported Q2 2024 financial results and business highlights. Key points include:
1. Ongoing dose expansion in TNG908 and TNG462 phase 1/2 clinical trials, with a comprehensive PRMT5 program update expected in 2H 2024.
2. TNG260 phase 1/2 clinical trial patient enrollment continues.
3. Strong cash position of $322.1 million as of June 30, 2024, with runway into 2027.
4. Q2 2024 financial results: Collaboration revenue $7.8 million, license revenue $12.1 million, R&D expenses $38.7 million, G&A expenses $10.8 million, net loss $25.6 million ($0.24 per share).
5. Gilead licensed a drug discovery program for a $12.0 million fee in June.
Tango Therapeutics (NASDAQ: TNGX), a clinical-stage biotech company specializing in precision cancer medicines, announced that CEO Barbara Weber, M.D., will present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 11, 2024, at 2:40 PM ET. The presentation will be webcast live on the company's website under the 'Events & Presentations' tab on the 'Investors' page, and a replay will be available for 90 days post-event.
Medivir announced that its licensee, Tango Therapeutics, has discontinued the clinical development of TNG348, a USP1 inhibitor aimed at treating BRCA1/2-mutant and HRD+ cancers, due to toxicity observed in phase 1/2 trials. The program was initially licensed from Medivir in 2020. Despite this setback, Medivir emphasized it remains focused on its lead program, fostroxacitabine bralpamide (fostrox), targeting primary liver cancer. The company is accelerating activities to initiate a pivotal phase 2b study for fostrox, which has the potential to secure market approval for treating HCC patients who fail current first-line treatments, a market projected to be worth $2.5 billion annually by 2028.
Tango Therapeutics (NASDAQ: TNGX) has discontinued its TNG348 program following Phase 1/2 trial results indicating liver toxicity in patients. The company emphasizes patient safety as the primary reason for halting the development of TNG348, a USP1 inhibitor. This decision will allow Tango Therapeutics to redirect resources toward its PRMT5 and CoREST clinical programs, which remain on track. The company has extended its cash runway into 2027 and plans to provide a comprehensive clinical update on TNG908 and TNG462 in the latter half of the year.
Tango Therapeutics, Inc. (NASDAQ: TNGX) reported strong financial results for Q1 2024 with a cash position of $344 million. The company is progressing its clinical programs, including dose expansion in TNG908 and TNG462 trials, with clinical data expected in 2H 2024. Tango is well-funded through late 2026. The company welcomed Julie Carretero as Chief Human Resources Officer to support growth.
FAQ
What is the current stock price of Tango Therapeutics (TNGX)?
What is the market cap of Tango Therapeutics (TNGX)?
